MCM
ALDX icon

MAI Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

MAI Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.42K Buy
3,208
+3,179
+10,962% +$13.9K ﹤0.01% 3475
2025
Q4 		$151 Buy
+29
New +$149 ﹤0.01% 4099

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAI Capital Management's ALDX Position: Q1 2026 in Review

MAI Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 10,962% in Q1 2026, buying an estimated $13.9K and bringing the position to 3,208 shares worth $5.42K. The position accounts for ﹤0.01% of the portfolio, ranked #3475.

MAI Capital Management first reported a position in ALDX in Q4 2025 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • MAI Capital Management held 3,208 shares of Aldeyra Therapeutics worth $5.42K as of Q1 2026.
  • MAI Capital Management bought 3,179 Aldeyra Therapeutics shares in Q1 2026, an estimated $13.9K.
  • Aldeyra Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3475 holding.
  • MAI Capital Management first reported a position in Aldeyra Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.